Business Wire

Index Ventures Announces $2.3bn in New Funds at a Historical Inflection Point for Startups

10.7.2024 07:30:00 EEST | Business Wire | Press release

Share

Index Ventures, a leading global venture capital firm, today announced $2.3 billion in new funds to forge relationships with exceptional entrepreneurs who are creating transformative, category-defining businesses. Combined with Index’s existing $300 million Origin seed fund, Index is deploying $2.6 billion in capital to back founders from seed to IPO. This brings Index’s total capital raised since its founding to $15 billion.

The firm’s fundraise comes at a pivotal moment for the global startup ecosystem. The rise of transformative technologies such as AI, the emergence of tried-and-tested playbooks for hyper-growth companies, and the critical mass of experienced global talent are feeding into and accelerating one another. The result is that entrepreneurs stand at a historical tipping point in which they have unprecedented opportunities to create new, category-defining businesses.

AI opens up entirely new industries for VC investment

“Even though technology has transformed our daily lives, the reality is that it has so much further to go,” said Shardul Shah, partner at Index Ventures. “AI alone will revolutionize virtually every sector of the economy and open up whole industries to venture that have remained virtually untouched. Meanwhile, hundreds of thousands of people have worked in hypergrowth startups globally and can transfer those lessons to the next generation of companies. We’re energized by the unique opportunities that this historical moment presents and excited to partner with founders to solve the world’s trickiest and most consequential problems.”

One global team: from SF to NY, London to Tel Aviv

With its new $800 million venture fund and $1.5 billion growth fund, Index is positioned to be the best long-term partner for entrepreneurs building upon this new foundation wherever they are in the world. Index has a meaningful presence from San Francisco in the West to Tel Aviv in the East – spanning ten time zones and 24 of the world’s 30 most vibrant ecosystems. Established on the West Coast with a portfolio that includes Figma, Discord, Notion, and Roblox, Index has stepped up its US presence with a new New York office. This means it can partner closely with category leaders like Datadog, as well as startups such as Wiz and DataSnipper, using New York as a bridge to help them expand from Europe and Israel across the US. Index has continued strengthening its US leadership by welcoming former Airbnb executive Vlad Loktev to the San Francisco office, who was instrumental in driving Airbnb’s growth and product strategy for over a decade at the company.

Three decades of investing: 108 unicorns, 57 IPOs, 200,000 jobs

Index has a nearly three-decade history of identifying, nurturing, and partnering with visionary founders. Most of these partnerships begin early in a company’s life, at Seed and Series A. Index has invested in 109 companies that reached a $1 billion valuation, 23 that exceeded a $10 billion valuation, and 57 that became publicly traded. The businesses in the Index portfolio have created 200,000 jobs so far and are on track to hire 20,000 more in the next 12 months. Recent highlights from the Index portfolio include:

  • Wiz, the cloud security company in which Index was an early investor, grew to 100x its value within 18 months – becoming the fastest-ever company to hit $100m ARR in that time. Wiz has now reached over $350m in ARR and serves over 40% of the Fortune 100;
  • Scale AI recently raised $1bn and doubled its valuation to $14 billion, and its data foundry powers nearly every leading large language model;
  • DeepL, the language AI company, is transforming the language industry, which is projected to grow to $95.3 billion by 2028. Index led DeepL’s $300M raise at a $2 billion valuation earlier this year;
  • Revolut, the all-in-one finance platform, announced revenues exceeding $2.2 billion for 2023, with record pre-tax profits of $545 million and 45 million customers globally

When Index’s founders succeed, they generate outsized returns for the firm’s limited partners, which include non-profit foundations, educational endowments, healthcare and research institutions, and other impact-oriented organizations.

About Index Ventures

Index Ventures is a global venture capital firm that backs exceptional entrepreneurs. We help founders turn their bold ideas into global businesses and, through the companies they build, have a long-lasting and positive impact on the world around us. Index-backed businesses are supported by an experienced team of investors, strategists, and an extensive global network built over three decades of startup investing. Working side-by-side through the scale-up journey, we forge deep and long-lasting relationships with founders and their teams across many industries and geographies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240709136755/en/

Contacts

Press Contact:
Kelsey Miller
press@indexventures.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release

Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

Speech Processing Solutions Launches Philips SpeechLive Legal AI Assistant for Faster, More Accurate Legal Document Creation5.8.2026 16:37:00 EEST | Press release

Speech Processing Solutions, the global leader in AI-assisted professional dictation and documentation solutions sold under the Philips brand, today announced the Philips SpeechLive Legal AI Assistant. The new solution transforms voice recordings, dictation and uploaded sources into structured, ready-to-review legal documents, helping legal professionals work faster while retaining control of the final draft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805997413/en/ The new Philips SpeechLive Legal AI Assistant is designed for turning conversations into ready-to-review legal document drafts. SpeechLive Legal significantly reduces the time needed to transform voice input into structured legal documentation, delivering consistent and high-quality drafts and featuring SpeechLive's built-in integrations with leading case management platforms such as Actionstep, Clio, iManage and NetDocuments, supporting existing billing, e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye